ARTICLES| VOLUME 395, ISSUE 10238, P1715-1725, MAY 30, 2020 Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study Amitava Banerjee, Laura Pasea, Steve Harris, et al Lancet 2020; 395: 1715-1725 Summary Background The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Pre...

ORIGINAL ARTICLE Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Jason D. Goldman, David C.B. Lye, David S. Hui, et al N Engl J Med May 27, 2020DOI: 10.1056/NEJMoa2015301 Abstract BACKGROUND Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). METHODS We conducted a randomized, open-label, phase 3 trial involving hospitalized patients wit...

Research Letter April 27, 2020 Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment Oren Feldman, Michal Meir, Danielle Shavit, et al JAMA. 2020;323(20):2091-2093. doi:10.1001/jama.2020.6633 A major challenge with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is the effective protection of health care workers.1 Recommendations for t...

ARTICLES|ONLINE FIRST Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Feng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, et al Lancet Published:May 22, 2020 DOI: https://doi.org/10.1016/S0140-6736(20)31208-3 Summary Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity...

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Mandeep R Mehra, Sapan S Desai, Frank Ruschitzka, et al Lancet Published Online May 22, 2020 https://doi.org/10.1016/S0140-6736(20)31180-6 Summary Background Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their...

ORIGINAL ARTICLE Remdesivir for the Treatment of Covid-19 — Preliminary Report John H. Beigel, Kay M. Tomashek, Lori E. Dodd, et al N Engl J Med May 22, 2020DOI: 10.1056/NEJMoa2007764 Abstract BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous r...

CORRESPONDENCE Covid-19 and Kidney Transplantation NEJM April 24, 2020DOI: 10.1056/NEJMc2011117 TO THE EDITOR: Kidney-transplant recipients appear to be at particularly high risk for critical Covid-19 illness due to chronic immunosuppression and coexisting conditions.1 At Montefiore Medical Center, we identified 36 consecutive adult kidney-transplant recipients who tested positive for Covid-19 between March 16 and April 1, 2020. A total of 26 recipients (...

Research Letter May 15, 2020 Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure Xavier Elharrar, Youssef Trigui, Anne-Marie Dols, et al JAMA. Published online May 15, 2020. doi:10.1001/jama.2020.8255 Patients with coronavirus disease 2019 (COVID-19) are at risk for acute respiratory distress syndrome.1 In intubated patients with severe acute respiratory distress syndrome, early and prolonged (...

April 14, 2020 Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial Nina Singh, Drew J. Winston, Raymund R. Razonable, et al. JAMA. 2020;323(14):1378-1387. doi:10.1001/jama.2020.3138 Abstract Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral prophylaxis for high-risk CMV-seronegative ...